ALCOHOL intake plays a significant role in shaping liver disease progression, with new large-scale data showing that reducing alcohol consumption can improve long-term outcomes in patients with steatotic liver disease (SLD).
SLD is characterised by excess fat accumulation in the liver and encompasses subtypes driven by alcohol exposure and metabolic dysfunction. These include alcohol-related liver disease (ALD), metabolic dysfunction-associated SLD (MASLD), and an overlapping category where both factors contribute to disease.
New evidence suggests that transitions between these subtypes, largely influenced by changes in alcohol intake, are closely tied to future liver-related events.
Modifying Alcohol Intake Reshapes Liver Disease Risk
In a nationwide cohort of more than 2.7 million Korean adults, researchers tracked changes alcohol intake and liver health over two health assessments. Participants were subsequently followed from 2013 to 2022 for liver-related events.
Individuals who maintained low alcohol intake and remained within the MASLD category consistently showed the most favourable prognosis, with the lowest risk of composite liver-related events.
By contrast, movement towards heavier drinking patterns—reflected by transitions towards ALD—correlated with a marked rise in adverse liver outcomes. The risk of liver-related events nearly doubled among those shifting from MASLD to ALD.
Even intermediate shifts, such as from MASLD to mixed metabolic and alcohol-related disease (MetALD), were associated with measurable increases in risk alongside worsening metabolic markers, including blood pressure and glucose.
Importantly, transitions towards lower alcohol intake were linked to reduced risk, suggesting that even partial reductions in drinking may alter disease trajectory.
Metabolic Factors Also Shape Outcomes
While alcohol intake emerged as a key driver, metabolic dysfunction also played an important role in disease progression. Increases in cardiometabolic risk markers, including systolic blood pressure and fasting glucose, were linked to higher liver-related risk, even in the absence of excessive alcohol intake, reinforcing the multifactorial nature of SLD.
Limitations of Alcohol Intake Findings
Despite its scale, the cohort was predominantly male, with 77.9% of participants being men. This may limit how well the results translate to female populations, which is particularly relevant given recognised sex differences in alcohol metabolism and susceptibility to liver injury.
As an observational analysis, the findings demonstrate associations between alcohol intake, metabolic factors, and liver outcomes, but cannot establish direct causality. Changes in drinking behaviour may coincide with other lifestyle or health modifications that also influence disease progression.
Implications for Clinical Practice
The findings support a shift away from static disease classification towards ongoing reassessment of liver disease subtype. Regular evaluation of alcohol intake and metabolic risk factors may enable more timely and individualised care.
Integrated management strategies—combining alcohol reduction support with treatment of metabolic risk factors—are likely to be critical, particularly for patients in higher-risk categories such as MetALD and ALD.
Reference
Jang S et al. Alcohol-driven phenotypic transition in MASLD and risk of liver-related events. JHEP Reports. 2026;DOI:10.1016/j.jhepr.2026.101866.
Featured image: Prostock-studio on Adobe stock
